Navigation Links
OncoSec Releases Devices for Use in Clinical Trials
Date:10/5/2011

SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology™ therapies to treat solid tumor cancers, announced today that the OncoSec Medical System (OMS) devices have been qualified and released and are now ready for shipment to clinical sites in time for the upcoming OMS ElectroImmunotherapy™ clinical trials.

(Photo: http://photos.prnewswire.com/prnh/20111005/LA80865)

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

In March 2011 OncoSec acquired the rights to an electroporation delivery technology platform that can be used to efficiently deliver a chemotherapeutic or DNA-based cytokine agent for the treatment of solid tumors, which OncoSec has branded as the OncoSec Medical System (OMS). Since then, projects were initiated to establish engineering and manufacturing capabilities, as well as, transfer and update regulatory, design and manufacturing documentation, including implementing a new quality assurance system. Over the course of five months a manufacturing plan was executed to ensure that the devices acquired by OncoSec were safe and ready for use in clinical trials. The company now has inventory of OMS investigational devices adequate to support known and anticipated clinical study requirements well into 2013. OncoSec's current infrastructure and facility is designed to support manufacturing, assembly, testing, technical and regulatory support for multiple clinical trials in compliance with FDA and quality systems regulations.  The extent of OncoSec manufacturing operations allow the company to build and maintain the current device supply to support on-going and future clinical trials, scale up production as needed as well as design and develop a next generation OMS electroporation system
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
(Date:9/2/2015)... MARIETTA, Ga. , Sept. 2, 2015  MiMedx ... regenerative medicine company utilizing human amniotic tissue and ... and therapies for the Wound Care, Surgical, Orthopedic, ... healthcare, today corrected the inaccurate statements published by ... release of September 1, 2015. MTF,s ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... Inc., a privately,held biopharmaceutical company that specializes ... ophthalmic,pharmaceuticals, today reported the interim month three ... pharmacokinetic (PK) study of Medidur(TM) FA,which Alimera ... Iluvien(TM),if approved by the U.S. Food and ...
... developing proposals to fund clinical studies for early detection ... ... 25 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ), a ... the Small,Business Innovation Research (SBIR) and Small Business Technology Transfer,(SBTT) seed ...
Cached Medicine Technology:Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 2Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 3Small Business Innovation Research Program Awards Grant to Biomoda 2
(Date:9/3/2015)... ... 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... perspective on internal medicine keeps patients happy and healthy, something that is important to ... the season, but even more so in the fall, when holiday eating and seasonal ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... Lauderdale, FL (PRWEB) , ... September 02, 2015 ... ... for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by ... hospitalized Medicare patients – is likely to average approximately $71,000 or roughly 40% ...
Breaking Medicine News(10 mins):Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... study to identify the composition of bacterial populations on the ... Skin, which// is the largest organ in our body harbors ... previously. Researchers said that it appears that the skin, is ... quite novel. ,Researchers found evidence for 182 species ...
... during pregnancy could lead to diabetes and cardio vascular ... women. Among them, those who had a high BP ... atherosclerosis than their counterparts who had a normal BP. ... latest issue of ‘Hypertension’ suggests that calcification of the ...
... latest Government data, there is an alarming rise in suicides ... linked to the plummeting sale of// antidepressants. ,This ... also indicated that youth in their late teens resorted to ... Administration had issued a black box warning on the antidepressants ...
... conducted by Robert Wilson of Rush University Medical Centre of Chicago ... Alzheimer’s like// Dementia. People who are single or socially secluded are ... their life. ,According to this study, a group of ... age group of 80 for a period of four years. A ...
... Worldwide describes a lawsuit from CSPI -Center for Science in ... claims of their new drink. ,According to the ... more calories and hence, an aid to calorie ... soft drink is laced with EGCG or epigallocatechin gallate which ...
... pain in the jaw may be a sign of a heart ... Uruguay.// ,The symptoms are however often overlooked, and especially ... tooth or jaw ache without chest pains, the study said. ... were asked to indicate on a body chart where they experienced ...
Cached Medicine News:Health News:Human Skin Harbors Many More Types of Bacteria 2Health News:Human Skin Harbors Many More Types of Bacteria 3Health News:Human Skin Harbors Many More Types of Bacteria 4Health News:Human Skin Harbors Many More Types of Bacteria 5Health News:Support Claims With Science Not Magic, Beverage Owners Warned 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: